| 吴文忠.丙种球蛋白联合重组人干扰素α1b对病毒性脑炎患儿免疫功能及血清神经功能指标的影响[J].,2022,(7):1282-1285 |
| 丙种球蛋白联合重组人干扰素α1b对病毒性脑炎患儿免疫功能及血清神经功能指标的影响 |
| Effects of Gamma Globulin Combined with Recombinant Human Interferon α1b on Immune Function and Serum Neurological Function Indexes in Children with Viral Encephalitis |
| 投稿时间：2021-12-08 修订日期：2021-12-31 |
| DOI：10.13241/j.cnki.pmb.2022.07.018 |
| 中文关键词: 病毒性脑炎 儿童 丙种球蛋白 重组人干扰素α1b 免疫功能 神经功能 |
| 英文关键词: Viral encephalitis Children Gamma globulin Recombinant human interferon α1b Immunity Neurological function |
| 基金项目: |
|
| 摘要点击次数: 669 |
| 全文下载次数: 442 |
| 中文摘要: |
| 摘要 目的：探讨丙种球蛋白联合重组人干扰素?琢1b对病毒性脑炎患儿免疫功能及血清神经功能指标的影响，为临床诊治病毒性脑炎患儿提供合理方案。方法：选取2019年1月-2021年12月于我院诊治的病毒性脑炎患儿76例，按随机数字表法分为对照组和联合组，每组各38例，对照组单纯给予重组人干扰素α1b治疗，联合组给予丙种球蛋白联合重组人干扰素α1b治疗，比较两组治疗前后免疫功能及血清神经功能指标变化情况，比较两组临床疗效及不良反应发生情况，记录两组惊厥、发热、精神症状、意识障碍、抽搐等症状消失时间。结果：联合组治疗总有效率为97.37%（37/38），高于对照组的84.21%（32/38），差异有统计学意义（P<0.05）。联合组不良反应发生率10.53%（4/38）与对照组5.26%（2/38）比较差异无统计学意义（P>0.05）。两组治疗后免疫功能指标免疫球蛋白（Ig）A水平较治疗前均降低，且联合组低于对照组（P<0.05）；两组治疗后IgE、IgG水平较治疗前均升高，且联合组高于对照组（P<0.05）。两组治疗后神经功能指标S100B蛋白、神经元特异性烯醇化酶（NSE）、髓磷脂碱性蛋白（MBP）及神经生长因子（NGF）水平较治疗前均下降，且联合组低于对照组（P<0.05）。联合组的惊厥、发热、精神症状、意识障碍、抽搐等症状消失时间短于对照组，差异有统计学意义（P<0.05）。结论：采用丙种球蛋白联合重组人干扰素α1b治疗病毒性脑炎患儿可取得显著疗效，能减轻患儿脑组织损伤，提高患儿免疫功能，改善患儿临床症状，且用药不良反应少。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effect of gamma globulin combined with recombinant human interferon α1b on immune function and serum neurological function indexes in children with viral encephalitis, and to provide a reasonable solution for clinical diagnosis and treatment of children with viral encephalitis. Methods: 76 children with viral encephalitis treated in our hospital from January 2019 to December 2021 were randomly divided into control group and combination group, with 38 cases in each group.The control group was simply given recombinant human interferon α1b treatment, the combination group was given gamma globulin combined with recombinant human interferon α1b treatment, compare the changes of immune function and serum neurological function indexes between the two groups before and after treatment, compare the clinical efficacy and adverse reactions of the two groups, and record the disappearance time of convulsion, fever, mental symptoms, disturbance of consciousness, convulsions and other symptoms in the two groups. Results: The total effective rate of the combined group was 97.37% (37/38), which was higher than 84.21% (32/38) in the control group (P<0.05). The incidence of adverse reactions in the combined group was 10.53% (4/38) compared with 5.26% (2/38) in the control group, and there was no significant difference (P>0.05). The level of immunoglobulin (Ig) A of immune function indexes in the two groups after treatment was lower than that before treatment, and that in the combined group was lower than that in the control group (P<0.05); After treatment, the levels of IgE and IgG in the two groups were higher than those before treatment, and the combination group was higher than the control group (P<0.05). After treatment, the levels of S100B protein, neuron specific enolase (NSE), myelin basic protein (MBP) and nerve growth factor (NGF) of neurological function indexes in the combined group were lower than those in the control group. The disappearance time of convulsion, fever, mental symptoms, disturbance of consciousness and convulsion in the combined group was shorter than that in the control group (P<0.05). Conclusion: Gamma globulin combined with recombinant human interferon α1b treatment of children with viral encephalitis can achieve significant curative effect, reduce brain tissue damage, improve immune function, improve clinical symptoms, and have less adverse drug reactions. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
